American Thoracic Society International Conference

Investigators from this ATS session suggested THN therapy could be used to treat OSA, believing in to be “a simpler approach than incumbent technology with no sensor and an easier, proximal electrode implantation”.

Research has indicated that a fixed-dose combination of albuterol and budesonide could better reduce the risk of severe asthma exacerbation when compared to albuterol alone.

Patients treated twice-daily with an 18 mg dose of BI 1015550 experienced prevention of decreased lung function regardless of any background antifibrotic agents.

While obesity is less common in pediatric sickle cell patients, BMI may impact airway resistance in this population.

In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

Where do investigators go next with the 8000-plus COPD patient research?

Both dosage groups of the study drug achieved at least a 50-meter increase from baseline to week 24 on the six-minute walk distance test.

Treatment with treprostinil of up to 12 breaths per session four-times per data was well-tolerated, with a safety profile consistent with previous studies.

In an era of triple therapy combinations, what might a tailored approach look like?

New findings from the 8000-plus patient ETHOS trial shows triple inhaler therapy siginificantly betters patient mortality and symptoms over 52 weeks versus dual therapy.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.

Asthmatic infants often suffer from other comorbidities throughout their lives.

Blood eosinophil count, exacerbation rate, and time to exacerbation were all bettered among patients who sustained therapy versus those who discontinued.

In an abstract presenting during the ATS conference, investigators find infants with asthma are surprisingly older on the epigentic clock.

Obstructive sleep apnea can be linked to the development of non-alcoholic fatty liver disease.

New findings from ATS show the residual effects of vaping-associated lung distress.

The lead PATHWAY investigator explains the intent and outcomes from the most recent phase 2B findings.

In a new study presented at ATS, investigators find CPAP withdrawal worsens the augmentation index.

A discussion with a study author on promising new findings for the combination inhaler therapy.

Infants with obstructive sleep apnea may also be at an increased risk of negative outcomes associated with COVID-19.

There are a number of reasons why identifying obstructive sleep apnea in infants is difficult, but new research shows feeding dysfunction could be an early link.

Little is understood about the systemic markers of worsening COPD. Investigators have observed at least 3 novel pathways.

A new assessment shows risk reduction is even more significant among COPD patients who have smoked.

Patients with OSA during REM sleep experience lower oxygen saturation and longer times with oxygen saturation.

Individuals with obstructive sleep apnea were more frequently male, obese, and had more coronary heart disease when compared to those without OSA.

A six-month study shows the common OSA therapy could have long-term benefit for reducing eventual cardiovascular risk.

Treatment drug results in a significant reduction in severe exacerbations for patients with eosinophil ≥150 cells/µL.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A 52-week assessment shows patients of varying interleukin serum levels equally benefitted from the TSLP inhibitor.